
    
      Each tumour will be assessed by itself. Regorafenib 40 mg tablets will be used in the study.
      Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle
      (i.e., 3 weeks on, 1 week off).

      Subjects will continue on treatment until at least one of the following occurs (main
      criteria):

        -  Progressive Disease (PD) by radiological assessments or clinical progression

        -  Death

        -  Unacceptable toxicity

        -  Subject withdraws consent

        -  Treating physician determines discontinuation of treatment is in the subject's best
           interest

        -  Substantial non-compliance with the protocol
    
  